[go: up one dir, main page]

MX2010003803A - Formas solidas del acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-tr ifluoro-1-(3'-metoxibifenil-4-ilo)etoxi)pirimidin-4-ilo)propanoic o y los metodos para su uso. - Google Patents

Formas solidas del acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-tr ifluoro-1-(3'-metoxibifenil-4-ilo)etoxi)pirimidin-4-ilo)propanoic o y los metodos para su uso.

Info

Publication number
MX2010003803A
MX2010003803A MX2010003803A MX2010003803A MX2010003803A MX 2010003803 A MX2010003803 A MX 2010003803A MX 2010003803 A MX2010003803 A MX 2010003803A MX 2010003803 A MX2010003803 A MX 2010003803A MX 2010003803 A MX2010003803 A MX 2010003803A
Authority
MX
Mexico
Prior art keywords
amino
pyrimidin
trifluoro
ethoxy
phenyl
Prior art date
Application number
MX2010003803A
Other languages
English (en)
Inventor
Wenxue Wu
Shinya Iimura
Hui-Yin Li
Qiuling Song
Matthew Mangzhu Zhao
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003803(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of MX2010003803A publication Critical patent/MX2010003803A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen las formas solidas del acido (S)-2-amino-3-(4-(2-amin o-6-((R)-2,2,2-trifluoro-1-(3?-metoxibifenil-4-ilo)etoxi)pirimidi n-4-ilo)fenil)propan?ico y las sales de este.
MX2010003803A 2007-10-08 2008-10-07 Formas solidas del acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-tr ifluoro-1-(3'-metoxibifenil-4-ilo)etoxi)pirimidin-4-ilo)propanoic o y los metodos para su uso. MX2010003803A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97830307P 2007-10-08 2007-10-08
PCT/US2008/079042 WO2009048864A1 (en) 2007-10-08 2008-10-07 Solid forms of (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use

Publications (1)

Publication Number Publication Date
MX2010003803A true MX2010003803A (es) 2010-04-21

Family

ID=40344344

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003803A MX2010003803A (es) 2007-10-08 2008-10-07 Formas solidas del acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-tr ifluoro-1-(3'-metoxibifenil-4-ilo)etoxi)pirimidin-4-ilo)propanoic o y los metodos para su uso.

Country Status (20)

Country Link
US (1) US20090099206A1 (es)
EP (1) EP2231618A1 (es)
JP (1) JP2010540665A (es)
KR (1) KR20100066548A (es)
CN (1) CN101932563A (es)
AR (1) AR068837A1 (es)
AU (1) AU2008310979A1 (es)
BR (1) BRPI0818350A2 (es)
CA (1) CA2701904A1 (es)
CL (1) CL2008002980A1 (es)
CO (1) CO6270323A2 (es)
EA (1) EA201070455A1 (es)
EC (1) ECSP10010162A (es)
IL (1) IL204582A0 (es)
MX (1) MX2010003803A (es)
PE (1) PE20091213A1 (es)
TW (1) TW200932729A (es)
UY (1) UY31381A1 (es)
WO (1) WO2009048864A1 (es)
ZA (1) ZA201001870B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855291B2 (en) * 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
ES2684821T3 (es) 2005-12-29 2018-10-04 Lexicon Pharmaceuticals, Inc. Derivados de aminoácidos multicíclicos y métodos de su uso
US7897763B2 (en) 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
CN101969952A (zh) * 2007-06-26 2011-02-09 莱西肯医药有限公司 包含色氨酸羟化酶抑制剂的组合物
TWI439457B (zh) 2007-09-28 2014-06-01 Lexicon Pharmaceuticals Inc （ｓ）－２－胺基－３－（４－（２－胺基－６－（（ｒ）－１－（４－氯－２－（３－甲基－１ｈ－吡唑－１－基）苯基）－２，２，２－三氟乙氧）－嘧啶－４－基）苯基）丙酸乙酯之固體形式與其使用方法
WO2009123978A1 (en) 2008-03-31 2009-10-08 The Trustees Of Columbia University In The City Of New York Methods of diagnosing, preventing and treating bone mass diseases
AU2010321905A1 (en) * 2009-11-23 2012-05-24 Lexicon Pharmaceuticals, Inc. Methods and assays for the treatment of irritable bowel syndrome
WO2013148978A1 (en) * 2012-03-30 2013-10-03 Lexicon Pharmaceuticals, Inc. Methods and compositions for the treatment of necrotizing enterocolitis
CN113227093A (zh) * 2018-11-14 2021-08-06 阿尔塔万特科学公司 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法
US20230348390A1 (en) * 2020-05-28 2023-11-02 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Method for preparing methyl(s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenylpropionate and salt thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7382793B1 (en) * 2002-01-17 2008-06-03 Juniper Networks, Inc. Systems and methods for determining the bandwidth used by a queue
US7855291B2 (en) * 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
ES2684821T3 (es) * 2005-12-29 2018-10-04 Lexicon Pharmaceuticals, Inc. Derivados de aminoácidos multicíclicos y métodos de su uso
US7897763B2 (en) * 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
CN101969952A (zh) * 2007-06-26 2011-02-09 莱西肯医药有限公司 包含色氨酸羟化酶抑制剂的组合物
KR20100037047A (ko) * 2007-06-26 2010-04-08 렉시컨 파마슈티컬스 인코퍼레이티드 세로토닌-매개 질환 및 장애의 치료 방법
KR20100046189A (ko) * 2007-07-11 2010-05-06 렉시컨 파마슈티컬스 인코퍼레이티드 폐고혈압 및 관련 질환 및 장애의 치료를 위한 방법 및 조성물
KR20100055436A (ko) * 2007-07-26 2010-05-26 렉시컨 파마슈티컬스 인코퍼레이티드 위장관 통과 및 위 배출에 영향을 주는 방법, 및 그에 유용한 화합물

Also Published As

Publication number Publication date
BRPI0818350A2 (pt) 2017-10-10
CA2701904A1 (en) 2009-04-16
KR20100066548A (ko) 2010-06-17
EP2231618A1 (en) 2010-09-29
EA201070455A1 (ru) 2010-08-30
JP2010540665A (ja) 2010-12-24
US20090099206A1 (en) 2009-04-16
IL204582A0 (en) 2010-11-30
UY31381A1 (es) 2009-04-30
AU2008310979A1 (en) 2009-04-16
CN101932563A (zh) 2010-12-29
ZA201001870B (en) 2011-06-29
CO6270323A2 (es) 2011-04-20
PE20091213A1 (es) 2009-08-26
WO2009048864A1 (en) 2009-04-16
AR068837A1 (es) 2009-12-09
TW200932729A (en) 2009-08-01
CL2008002980A1 (es) 2009-03-20
ECSP10010162A (es) 2010-06-29

Similar Documents

Publication Publication Date Title
MX2010003803A (es) Formas solidas del acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-tr ifluoro-1-(3'-metoxibifenil-4-ilo)etoxi)pirimidin-4-ilo)propanoic o y los metodos para su uso.
SI3057943T1 (en) Pyrimidine FGFR4 Inhibitors
EA201190296A1 (ru) Дисахариновая, дифумарово-кислая, ди-1-гидрокси-2-нафтойно-кислая и монобензойно-кислая соли 4-(диметиламино)бутил-2-(4-((2-амино-4-метил-6-(пентиламино)пиримидин-5-ил)метил)фенил)ацетата
CR11007A (es) Formulaciones estables de de acido s-(+)- abscisico liquidas y de granulo soluble
JO3061B1 (ar) صور بلورية من 3- ( 2، 6- ثانى كلورو – 3، 5- ثانى ميثوكسى فينيل) – 1- { 6- [ 4- (4- ايثيل – بيبرازين – 1- يل) – فينيل أمينو ] – بيريميدين – 4- يل } – 1- ميثيل – يوريا وأملاح منها
BRPI0811745A2 (pt) Uso de compostos de 4-(pirrolidin-1-il)quinolina para matar micro-organismos clinicamente latentes
CY1111170T1 (el) Ενωσεις διαρυλ αιθερα ουριας
TN2010000237A1 (en) Novel compounds and compositions and methods of use
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
WO2012020848A8 (en) Heterocyclic compound and use thereof
EA200802214A1 (ru) 2,4-диаминопиримидины в качестве ингибиторов киназ, участвующих в регуляции клеточного цикла
BR112013020767A2 (pt) composições compreendendo ácido peróxi alfa-cetocarboxílico e métodos para a produção e o uso do mesmo
ECSP10010076A (es) Formas Sólidas de (S)-etil-2-amino-3-(4 - (2-amino-6-((R) -1 - (4-cloro-2-(3-metil-1H-pirazol-1-YL ) fenil) -2,2,2-trifluoroetoxi)-pirimidina-4-il) fenil) propanoato y Métodos de su Uso
GEP20166488B (en) Co-crystals and salts of ccr3-inhibitors
PH12014500997B1 (en) 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
MA32717B1 (fr) Sels de n-[6-cis- (2.6-dimethylmorpholin-4-yl)pyridin-3-yl)-2-methyl-4'- (trifluoromethoxy)- [1.1'-biphenyl]-3-carboxamide
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
NZ602710A (en) Use of novel pan-cdk inhibitors for treating tumors
EA201290504A1 (ru) Новые производные (конденсированный гетероцикл-пиперидин)-(пиперазинил)-1-алканона или (конденсированный гетероцикл-пирролидин)-(пиперазинил)-1-алканона и их применение в качестве ингибиторов р75
BR112013011015A2 (pt) formas sólidas de ácido (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetóxi)pirimidin-4-il)fenil)propanoico
EA201200855A1 (ru) Модуляторы crth2
SG195170A1 (en) Methods of treating or preventing rheumatic disease
FR2911278B1 (fr) Procede d'obtention d'un actif cosmetique depigmentant, principe actif obtenu et compositions l'incluant
EA201170016A1 (ru) Новые производные (пиперазинил мостиковый)-1-алканона и их применение в качестве ингибиторов р75
MA38135A2 (fr) Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium

Legal Events

Date Code Title Description
FA Abandonment or withdrawal